My eyeballing of the interrum results looks like the ATG group used about 60% as much insulin as the untreated group after about 12 months, and this seemed pretty stable. It did not look to me like the effect was "wearing off". This was good enough to motivate a follow-on, phase-II clinical trial, which is currently underway. I'm also very interested in what happens to these 17 patients after 2 years, 3 years etc. If the lower insulin requirement gradually goes away, that's too bad. If it stays stable, then that is very promising. If it gets even better slowly over time, that suggests that the body is growing new beta cells, and would be good news both for ATG treatments and for many others.
US Government Clinical Trial Record: http://clinicaltrials.gov/ct2/show/NCT00190502
|Study Start Date:||November 2000|
|Estimated Study Completion Date:||December 2007|
This work was sponsored by the Ministry of Health, Czech Republic, and is being done in Prague.